Payment overview · 2025
General Payments
$995.14
57 reported records · 22 companies
Healthcare provider profile · identity verified
Sarika Sharma, M.D.
Allopathic & Osteopathic Physicians|General Practice · HACKENSACK, NJ · NPI 1821042771
Verified facts
What the public records show
CMS Open Payments records show Sarika Sharma, M.D. received $995.14 in general payments during 2025 across 57 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Farxiga, Jardiance, Kerendia, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Edarbyclor by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $225.60 | 22.7% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $160.43 | 16.1% | 9 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $68.95 | 6.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.53 | 6.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.96 | 6.3% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $52.98 | 5.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.41 | 5.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.65 | 4.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.50 | 4.0% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $21.14 | 2.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.88 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.24 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.09 | 1.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.08 | 1.8% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.86 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.78 | 1.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.26 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.80 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.65 | 1.6% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $15.43 | 1.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.74 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.18 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $958.93 | 55 |
| Education | $36.21 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $225.60 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $119.60 | 7 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $68.95 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $66.53 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.96 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $52.98 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.41 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $48.65 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.52 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
207 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
207 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 618 | 168 |
| Atorvastatin Calcium | Atorvastatin Calcium | 435 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 392 | 124 |
| Losartan Potassium | Losartan Potassium | 386 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 375 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 275 | 69 |
| Famotidine | Famotidine | 237 | 85 |
| Metformin Hcl | Metformin Hcl | 233 | 61 |
| Eliquis | Apixaban | 207 | 41 |
| Furosemide | Furosemide | 196 | 56 |
| Gabapentin | Gabapentin | 196 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 57 |
| Carvedilol | Carvedilol | 186 | 51 |
| Montelukast Sodium | Montelukast Sodium | 161 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 39 |
| Metformin Hcl Er | Metformin Hcl | 129 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 127 | 29 |
| Ozempic | Semaglutide | 116 | 18 |
| Azithromycin | Azithromycin | 112 | 83 |
| Potassium Chloride | Potassium Chloride | 110 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 29 |
| Simvastatin | Simvastatin | 109 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 108 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 107 | 30 |
| Alprazolam | Alprazolam | 105 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 90 | 15 |
| Ezetimibe | Ezetimibe | 89 | 27 |
| Entresto | Sacubitril/Valsartan | 83 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 37 |
| Glimepiride | Glimepiride | 79 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 27 |
| Allopurinol | Allopurinol | 72 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 17 |
| Lorazepam | Lorazepam | 69 | 13 |
| Sertraline Hcl | Sertraline Hcl | 66 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 66 | 11 |
| Jardiance | Empagliflozin | 63 | 18 |
| Omeprazole | Omeprazole | 63 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 60 | 13 |
| Lisinopril | Lisinopril | 60 | 19 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Spironolactone | Spironolactone | 58 | 13 |
| Valsartan | Valsartan | 56 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 41 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Meloxicam | Meloxicam | 45 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 11 |
| Folic Acid | Folic Acid | 40 | 12 |
| Tradjenta | Linagliptin | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | 14 |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Digoxin | Digoxin | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 19 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Edarbi | Azilsartan Medoxomil | 31 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 19 |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 21 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 14 |
| Ramipril | Ramipril | 21 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Fluocinonide | Fluocinonide | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Zetia | Ezetimibe | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $995.14 · 57 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, AREXVY, Attruby, BREZTRI, Barostim Neo System, CAMZYOS, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, EDARBI, FARXIGA, GALLANT, JARDIANCE, Kerendia, Korlym, LEQVIO, LOKELMA, MOUNJARO, NEXLETOL, REPATHA, SHINGRIX, SYMPLICITY G3, The Cologuard Plus Collection Kit, VOQUEZNA, VYNDAQEL, WATCHMAN FLX, Wegovy, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error